Journal: Pharmaceutics

Article Title: Supercritical Antisolvent Technique for the Production of Breathable Naringin Powder

doi: 10.3390/pharmaceutics14081623

Figure Lengend Snippet: NuLi-1 cells treated for 24 h with raw naringin and SAE microparticles (SAE#7) at concentrations from 10 to 200 µM. Panel ( A ): Cell viability was determined by MTT assay. All data are shown as mean ± SD of three independent experiments, each performed in duplicate. Panel ( B ): Cell growth determined using a colorimetric bromodeoxyuridine cell proliferation ELISA kit. The histograms report the percentage of growing cells in comparison with untreated cells (control, 100% proliferation). All data are shown as mean ± SD of three independent experiments, each performed in duplicate (* p < 0.05 vs. control, ** p < 0.01 vs. control).

Article Snippet: The NuLi-1 cell line was purchased from American Type Culture Collection (ATCC, Manassas, VA, USA).

Techniques: MTT Assay, Enzyme-linked Immunosorbent Assay

Journal: Pharmaceutics

Article Title: Aerosolizable Lipid Nanoparticles for Pulmonary Delivery of mRNA through Design of Experiments

doi: 10.3390/pharmaceutics12111042

Figure Lengend Snippet: In vitro intracellular protein expression in terms of percent GFP expression and fluorescence intensity of LNP formulations before and after nebulization in HEK-293 ( a , c ) and NuLi-1 cells ( b , d ). a,b represent the percent GFP expression in HEK-293 and NuLi-1 cells, respectively. c,d represent the GFP fluorescence intensity in HEK-293 and NuLi-1 cells, respectively.

Article Snippet: LNP formulations were aerosolized by the Aerogen Solo (Aerogen Ltd., Galway, Ireland) nebulizer and the potency of each nebulized formulation was evaluated in HEK-293 and human bronchial epithelial NuLi-1 cell lines.

Techniques: In Vitro, Expressing, Fluorescence